Short-term Impact of Mass Drug Administration With Dihydroartemisinin Plus Piperaquine on Malaria in Southern Province Zambia: A Cluster-Randomized Controlled Trial
Thomas P Eisele, Adam Bennett, Kafula Silumbe, Timothy P Finn, Victor Chalwe, Mulakwa Kamuliwo, Busiku Hamainza, Hawela Moonga, Emmanuel Kooma, Elizabeth Chizema Kawesha, Joshua Yukich, Joseph Keating, Travis Porter, Ruben O Conner, Duncan Earle, Richard W Steketee, John M Miller, Thomas P Eisele, Adam Bennett, Kafula Silumbe, Timothy P Finn, Victor Chalwe, Mulakwa Kamuliwo, Busiku Hamainza, Hawela Moonga, Emmanuel Kooma, Elizabeth Chizema Kawesha, Joshua Yukich, Joseph Keating, Travis Porter, Ruben O Conner, Duncan Earle, Richard W Steketee, John M Miller
Abstract
Background: Mass drug administration (MDA) using dihydroartemisinin plus piperaquine (DHAp) represents a potential strategy to clear Plasmodium falciparum infections and reduce the human parasite reservoir.
Methods: A cluster-randomized controlled trial in Southern Province, Zambia, was used to assess the short-term impact of 2 rounds of community-wide MDA and household-level (focal) MDA with DHAp compared with no mass treatment. Study end points included parasite prevalence in children, infection incidence, and confirmed malaria case incidence.
Results: All end points significantly decreased after intervention, irrespective of treatment group. Parasite prevalence from 7.71% at baseline to 0.54% after MDA in lower-transmission areas, resulting in an 87% reduction compared with control (adjusted odds ratio, 0.13; 95% confidence interval, .02-.92; P = .04). No difference between treatment groups was observed in areas of high transmission. The 5-month cumulative infection incidence was 70% lower (crude incidence rate ratio, 0.30; 95% confidence interval, .06-1.49; P = .14) and 58% lower (0.42; .18-.98; P = .046) after MDA compared with control in lower- and higher-transmission areas, respectively. No significant impact of focal MDA was observed for any end point.
Conclusions: Two rounds of MDA with DHAp rapidly reduced infection prevalence, infection incidence, and confirmed case incidence rates, especially in low-transmission areas.
Clinical trials registration: NCT02329301.
Keywords: elimination; malaria; mass drug administration.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America.
Figures
References
- Chizema-Kawesha E, Miller JM, Steketee RW, et al. . Scaling up malaria control in Zambia: progress and impact 2005–2008. Am J Trop Med Hyg 2010; 83:480–8.
- Zambia Ministry of Health. National Malaria Control Programme strategic plan for FY 2011–2015: consolidating malaria gains for impact. Lusaka, Zambia: National Malaria Control Programme, 2011.
- Tiono AB, Ouedraogo A, Ogutu B, et al. . A controlled, parallel, cluster-randomized trial of community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso. Malar J 2013; 12:79.
- Larsen DA, Bennett A, Silumbe K, et al. . Population-wide malaria testing and treatment with rapid diagnostic tests and artemether-lumefantrine in southern Zambia: a community randomized step-wedge control trial design. Am J Trop Med Hyg 2015; 92:913–21.
- Cook J, Xu W, Msellem M, et al. . Mass screening and treatment on the basis of results of a Plasmodium falciparum-specific rapid diagnostic test did not reduce malaria incidence in Zanzibar. J Infect Dis 2015; 211:1476–83.
- Sutcliffe CG, Kobayashi T, Hamapumbu H, et al. . Reduced risk of malaria parasitemia following household screening and treatment: a cross-sectional and longitudinal cohort study. PLoS One 2012; 7:e31396.
- Halliday KE, Okello G, Turner EL, et al. . Impact of intermittent screening and treatment for malaria among school children in Kenya: a cluster randomised trial. PLoS Med 2014; 11:e1001594.
- Stresman GH, Baidjoe AY, Stevenson J, et al. . Focal screening to identify the subpatent parasite reservoir in an area of low and heterogeneous transmission in the Kenya highlands. J Infect Dis 2015; 212:1768–77.
- Okell LC, Bousema T, Griffin JT, Ouedraogo AL, Ghani AC, Drakeley CJ. Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat Commun 2012; 3:1237.
- McMorrow ML, Aidoo M, Kachur SP. Malaria rapid diagnostic tests in elimination settings—can they find the last parasite? Clin Microbiol Infect 2011; 17:1624–31.
- Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J. Mass drug administration for malaria. Cochrane Database Syst Rev 2013; 12:CD008846.
- von Seidlein L, Greenwood BM. Mass administrations of antimalarial drugs. Trends Parasitol 2003; 19:452–60.
- Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev 2014; 1:CD010927.
- Sawa P, Shekalaghe SA, Drakeley CJ, et al. . Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis 2013; 207:1637–45.
- World Health Organization. Disease surveillance for malaria elimination. Geneva, Switzerland: World Health Organization, 2012.
- Eisele TP, Silumbe K, Finn T, et al. . Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials 2015; 16:347.
- Zambia Ministry of Health. Guidelines on diagnosis and treatment of malaria in Zambia. 4th ed. Lusaka, Zambia: Zambian Ministry of Health, 2014.
- Newby G, Hwang J, Koita K, et al. . Review of mass drug administration for malaria and its operational challenges. Am J Trop Med Hyg 2015; 93:125–34.
- Song J, Socheat D, Tan B, et al. . Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine. Malar J 2010; 9:57.
- Kaneko A, Taleo G, Kalkoa M, Yamar S, Kobayakawa T, Bjorkman A. Malaria eradication on islands. Lancet 2000; 356:1560–4.
- Huehne WH. Experience with an insecticide-drug combination and observations on suppressive chloroquine-pyrimethamine treatment. J Trop Med Hyg 1971; 74:110–6.
- Dapeng L, Leyuan S, Xili L, Xiance Y. A successful control programme for falciparum malaria in Xinyang, China. Trans R Soc Trop Med Hyg 1996; 90:100–2.
- Gabaldon A, Guerrero L. An attempt to eradicate malaria by the weekly administration of pyrimethamine in areas of out-of-doors transmission in Venezuela. Am J Trop Med Hyg 1959; 8:433–9.
- Garfield RM, Vermund SH. Changes in malaria incidence after mass drug administration in Nicaragua. Lancet 1983; 2:500–3.
- Shekalaghe SA, Drakeley C, van den Bosch S, et al. . A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malar J 2011; 10:247.
- von Seidlein L, Walraven G, Milligan PJ, et al. . The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Trans R Soc Trop Med Hyg 2003; 97:217–25.
- Gerardin J, Eckhoff P, Wenger EA. Mass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination. BMC Infect Dis 2015; 15:144.
- Gerardin J, Bever CA, Hamainza B, Miller JM, Eckhoff PA, Wenger EA. Optimal population-level infection detection strategies for malaria control and elimination in a spatial model of malaria transmission. PLoS Comput Biol 2016; 12:e1004707.
- Keating J, Miller J, Bennett A, Moonga H, Eisele T. Plasmodium falciparum parasite infection prevalence from a household survey in Zambia using microscopy and a rapid diagnostic test: implications for monitoring and evaluation. Acta Trop 2009; 112:277–82.
Source: PubMed